13 results about "Disulfiram" patented technology

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The invention discloses an application of charantin IV in preparation of a tumor treatment medicine. The invention provides and verifies that the charantin IV can significantly inhibit the activity of cancer cells by inducing disulfiram death of cancer cells for the first time, can further promote gefitinib to overcome the drug resistance of cancer cells and inhibit the progress of drug-resistant tumors, and provides a new direction and theoretical basis for drug research, development and treatment of gefitinib drug-resistant non-small cell lung cancer.

The invention provides application of disulfiram in preparation of a medicine for treating calcified aortic valve diseases, and belongs to the field of biological medicine. The disulfiram is used for intervening in-vitro cultured valvular interstitial cells and a mouse in-vivo calcified aortic valve stenosis model, and experimental results show that the disulfiram can inhibit the capability of differentiating the valvular interstitial cells to osteogenic phenotypes, relieve extracellular calcification deposition and relieve aortic valve calcification and stenosis. Therefore, the disulfiram can be used as a medicine for treating the calcified aortic valve disease and has a wide application prospect.

The invention provides application of a preparation for activating RIPKs / MLKL mediated necroptosis signal transduction in preparation of a medicine for reversing taxol drug resistance of ovarian cancer, and belongs to the technical field of biological medicine. It is found for the first time that disulfiram (DSF) can reverse ovarian cancer paclitaxel drug resistance and enhance sensitivity of ovarian cancer paclitaxel drug-resistant cells to paclitaxel. A further research discovers that the DSF is used for enhancing RIPKs / MLKL mediated necroptosis signal transduction by combining an apoptosis-inducing factor (AIF), and finally, the chemosensitivity of the paclitaxel drug-resistant ovarian cancer cells is enhanced through a caspase-dependent apoptosis pathway. The invention deeply studies an ovarian cancer paclitaxel drug resistance mechanism, discovers a new application of DSF in reversing ovarian cancer paclitaxel drug resistance, and provides a new choice for treating paclitaxel drug-resistant ovarian cancer.

The invention discloses an application of a small molecule compound covalently bound with GSDMD in preparation of a pyroptosis inhibitor. Through deep research, a novel compound AF-966 / 00547018, called C6 for short, which can specifically target GSDMD protein and effectively inhibit the pore-forming activity of the GSDMD protein is screened, and the structure of the compound AF-966 / 00547018 is shown in the specification. Compared with reported pyroptosis inhibitors such as disulfiram, dimethyl fumarate and Necrosulfenamide (NSA), the C6 shows higher activity of inhibiting the pyroptosis of the cells, and the C6 shows higher activity of inhibiting the pyroptosis of the cells.

This invention discloses the application of disulfiram or its pharmaceutical salt in the preparation of radiosensitizers, wherein the radiosensitizer refers to a radiosensitizer for malignant tumors, specifically osteosarcoma. The radiation involved in the radiosensitizer is selected from alpha, beta, gamma, or X-ray radiation. This invention is the first to discover and confirm a novel use of disulfiram in enhancing the radiosensitivity of malignant tumors, significantly inhibiting the proliferation of osteosarcoma cells after radiotherapy and promoting cell death in vitro. It also demonstrates outstanding efficacy in inhibiting the growth of subcutaneously implanted osteosarcoma in mice after radiotherapy.

This invention relates to the field of biomedicine, and in particular to the application of disulfiram in the preparation of orthopoxvirus inhibitors. Disulfiram exhibits a significant inhibitory effect on orthopoxvirus by specifically binding to palmitic acid on the MPXV gp045 membrane protein. When the IC50 of disulfiram is 825 nM, it can significantly inhibit the spread of orthopoxvirus. In HeLa and Huh7.5.1 cells, its IC50 is 3022 nM and 7125 nM, respectively, which can significantly inhibit the formation of EEV, thereby preventing the further spread of orthopoxvirus and providing a more comprehensive intervention for anti-orthopoxvirus therapy.

The invention discloses a medicine for treating bronchial pulmonary dysplasia and application thereof, and relates to the field of medicine. The invention relates to a medicine for treating bronchial pulmonary dysplasia, which comprises a therapeutically effective amount of disulfiram and pharmaceutic adjuvants and is prepared into an injection, and the application of the medicine for treating bronchial pulmonary dysplasia is characterized in that release of lung tissue inflammatory factors IL-1beta and IL-18 is reduced by inhibiting GSDMD-mediated pyroptosis of macrophages, and the dosage is 40-60 [mu] g / (kg.d); the approach is intraperitoneal injection; and the medicine is continuously administrated for 7-10 days for treatment course. According to the application disclosed by the invention, the interaction mechanism between the GSDMD-mediated pyroptosis of macrophages and the chronic hyperxia-induced BPD is determined by constructing a chronic hyperxia-induced newborn mouse BPD model, and the newborn BPD is relieved by regulating the pyroptosis of the macrophages through the disulfiram, so that a new intervention measure and a new drug target are provided for clinical treatment.

Described are analogs of aztreonam and disulfiram of Formula I, II, and III. These compounds can be used to treat bacterial infections in a subject. Also disclosed is the use of aztreonam and disulfiram for treating H. pylori infections. Combinations of the disclosed analogs and / or aztreonam and disulfiram with additional antibiotics and proton pump inhibitors are also disclosed.

The invention discloses an application of carnosine in preparation of a medicine for improving pulmonary fibrosis, and belongs to the technical field of medicines. According to the present invention, the puberine VOM can induce disulfiram death by improving the protein expression level of the SLC7A11 of lung fibroblasts so as to alleviate the pulmonary fibrosis symptom, the treatment strategy of the pulmonary fibrosis disease can be further expanded, and the treatment of the pulmonary fibrosis by using the VOM has good application prospects.

The present invention is directed to methods of treating ophthalmic conditions comprising administration of disulfiram or a metabolite of disulfiram selected from the group consisting of sodium diethyldithiocarbamate, copper diethyldithiocarbamate, zinc diethyldithiocarbamate, lead diethyldithiocarbamate, nickel diethyldithiocarbamate, cadmium diethyldithiocarbamate, S-methyl-N,N-diethylthiocarbamate, S-methyl N,N-diethylthiocarbamate sulfoxide, S-methyl-N,N-diethylthiocarbamate sulfone, diethyldithiocarbamate and methyl diethyldithiocarbamate and hydrates thereof.

The invention provides a vascular intervention device and a preparation method and application thereof. In a first aspect, the present invention provides a vascular intervention device comprising an expandable balloon and a drug coating located on a surface of the balloon, the drug coating comprising a disulfiram (DSF). The disulfiram-containing drug coating is coated on the surface of the expandable balloon, the disulfiram can be efficiently transferred to a target blood vessel while the disulfiram-containing drug coating has stability, the disulfiram-containing drug coating plays a regulating role in an inflammatory microenvironment after a vascular intervention operation so as to resist restenosis, and the disulfiram-containing drug coating vascular intervention device is more targeted, more effective and safer.

The invention discloses an application of disulfiram in preparation of a medicine for treating lysosomal storage diseases. The drug disulfiram screened by the invention can inhibit phenotypes of lysosomal storage diseases, including inhibition of increase of lysosomal volume, inhibition of cholesterol storage, substantial recovery of inhibited lysosomal tubulation, substantial recovery of repeated hunger tolerance and reduction of cell death rate, thereby achieving the purposes of alleviating injury and inhibiting disease development. Therefore, the disulfiram has the prospect of being developed into the broad-spectrum medicine for treating the lysosomal storage disease.